Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- MR-1 nonpolymorphic micro-globulin HEK-293 Escherichia
- Product Overview:
MHC class I-related gene protein (MR1) is a non-polymorphic MHC class Ib antigen-presenting cell surface molecule that is required for T cell receptor-mediated activation of mucosal-associated invariant T (MAIT) cells.{60473,60472} MR1 is composed of ?1 and ?2 domains, which form an antigen-binding pocket, and an ?3 domain that interacts with ?2-microglobulin, the light chain component of MHC class I molecules that facilitates complex transport to the cell surface and antigen presentation to cytotoxic T cells.{60472,45065} Upon binding of a microbial antigen, MR1 undergoes a conformational change in the endoplasmic reticulum and translocates to the cell surface with ?2-microglobulin where it induces MAIT cell activation via an interaction with the MAIT cell T cell receptor and activates various immunomodulatory effects, including cytokine release, initiation of adaptive immune responses, and promotion of tissue repair.{45938,60474} The antigen-binding domain of MR1 binds to vitamin B metabolites, including metabolites of vitamin B2, also known as riboflavin, and vitamin B9 (folic acid; Item No. 20515).{45742} MHC class I-associated ?2-microglobulin exhibits equilibrium exchange with circulating soluble ?2-microglobulin and serum levels of ?2-microglobulin are increased in patients with cancer, renal failure, systemic amyloidosis, or various autoimmune diseases, including multiple sclerosis.{45065,45066,45067,45064}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.